Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
BMY logo BMY
Upturn stock ratingUpturn stock rating
BMY logo

Bristol-Myers Squibb Company (BMY)

Upturn stock ratingUpturn stock rating
$53.9
Delayed price
Profit since last BUY-6.2%
upturn advisory
SELL
SELL since 2 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

02/14/2025: BMY (1-star) is a SELL. SELL since 2 days. Profits (-6.20%). Updated daily EoD!

Upturn Star Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

AI Based Fundamental Rating

ratingratingratingratingrating

Below Average Performance

These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.

Analysis of Past Performance

Type Stock
Historic Profit 7.87%
Avg. Invested days 37
Today’s Advisory SELL
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 2.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 02/14/2025

Key Highlights

Company Size Large-Cap Stock
Market Capitalization 109.38B USD
Price to earnings Ratio -
1Y Target Price 61.24
Price to earnings Ratio -
1Y Target Price 61.24
Volume (30-day avg) 10946056
Beta 0.45
52 Weeks Range 38.18 - 61.10
Updated Date 02/15/2025
52 Weeks Range 38.18 - 61.10
Updated Date 02/15/2025
Dividends yield (FY) 4.60%
Basic EPS (TTM) -4.41

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date 2025-02-06
When Before Market
Estimate 1.4675
Actual 1.67

Profitability

Profit Margin -18.53%
Operating Margin (TTM) 22.66%

Management Effectiveness

Return on Assets (TTM) 6.55%
Return on Equity (TTM) -38.95%

Valuation

Trailing PE -
Forward PE 7.76
Enterprise Value 149720918039
Price to Sales(TTM) 2.26
Enterprise Value 149720918039
Price to Sales(TTM) 2.26
Enterprise Value to Revenue 3.1
Enterprise Value to EBITDA 47.26
Shares Outstanding 2029309952
Shares Floating 2025496916
Shares Outstanding 2029309952
Shares Floating 2025496916
Percent Insiders 0.34
Percent Institutions 80.74

AI Summary

Bristol-Myers Squibb Company (BMY): A Comprehensive Overview

Company Profile

Detailed History and Background:

Bristol-Myers Squibb (BMY) is a global biopharmaceutical company with a rich history dating back to 1858. It emerged from the 1989 merger of Bristol-Myers, established in 1858, and Squibb, founded in 1858. Today, BMY focuses on discovering, developing, and delivering innovative medicines in various therapeutic areas, including cardiovascular disease, oncology, immunology, and fibrosis.

Core Business Areas:

BMY operates through three primary segments:

  • Biopharmaceuticals: This segment focuses on developing and commercializing innovative medicines for various therapeutic areas, including oncology, cardiovascular disease, and immunology.
  • Global Markets: This segment focuses on commercializing BMY's medicines in various international markets outside the United States.
  • R&D: This segment focuses on discovering and developing new medicines and technologies for future pipeline growth.

Leadership Team and Corporate Structure:

BMY is led by a strong leadership team with extensive industry experience:

  • Giovanni Caforio, Chairman and CEO: Joined BMY in 2019, bringing over 30 years of experience in the pharmaceutical industry.
  • Christopher Boerner, Chief Operating Officer and President, Biopharmaceuticals: Joined BMY in 2012, with extensive experience in product development and commercialization.
  • David R. Elkins, Chief Financial Officer: Joined BMY in 2019, with over 25 years of experience in finance and accounting.

BMY's corporate structure is designed to ensure efficient and effective operations with clear lines of responsibility and accountability.

Top Products and Market Share

Top Products and Offerings:

BMY's top products include:

  • Revlimid (lenalidomide): A treatment for multiple myeloma and mantle cell lymphoma.
  • Opdivo (nivolumab): A treatment for various types of cancer.
  • Eliquis (apixaban): A blood thinner used to prevent blood clots.
  • Empliciti (elotuzumab): A treatment for multiple myeloma.
  • Orencia (abatacept): A treatment for rheumatoid arthritis.

Market Share Analysis:

BMY holds significant market share in several therapeutic areas:

  • Revlimid holds a dominant market share in the multiple myeloma market.
  • Opdivo is a leading player in the immuno-oncology market.
  • Eliquis is a major competitor in the blood thinner market.

Product Performance and Market Reception:

BMY's top products have generally been well-received by the market, demonstrating strong sales growth and positive clinical data. However, competition in these therapeutic areas is intense, and BMY faces challenges from other major pharmaceutical companies.

Total Addressable Market

BMY operates in a global market for biopharmaceuticals, representing a significant addressable market. The global pharmaceutical market is estimated to reach $1.57 trillion by 2023, with the oncology market alone valued at $200 billion.

Financial Performance

Recent Financial Performance:

BMY's recent financial performance has been strong, with consistent revenue growth and profitability. In 2022, BMY reported:

  • Revenue: $46.8 billion
  • Net income: $15.3 billion
  • Earnings per share (EPS): $7.26

Financial Performance Comparison:

BMY's financial performance has outpaced the broader pharmaceutical industry in recent years. Its revenue and earnings growth have consistently exceeded industry averages.

Cash Flow and Balance Sheet Health:

BMY generates strong cash flow from its operations, allowing it to invest in research and development, acquisitions, and shareholder returns. The company also maintains a healthy balance sheet with a low debt-to-equity ratio.

Dividends and Shareholder Returns

Dividend History:

BMY has a consistent history of paying dividends to shareholders. The company's current annual dividend yield is 3.1%, and its payout ratio is approximately 50%.

Shareholder Returns:

BMY has delivered strong shareholder returns over the past several years. Over the past 5 years, BMY's stock has returned an average of 15% annually, outperforming the S&P 500 index.

Growth Trajectory

Historical Growth:

BMY has experienced consistent revenue and earnings growth over the past 5-10 years, driven by the success of its top products and strategic acquisitions.

Future Growth Projections:

Analysts project BMY to continue growing its revenue and earnings in the coming years, driven by new product launches, market share gains, an expanding pipeline, and favorable industry trends.

Recent Product Launches and Strategic Initiatives:

BMY has recently launched several new products and initiatives to drive future growth, including:

  • Breyanzi (lisocabtagene maraleucel): A CAR-T cell therapy for adults with relapsed or refractory large B-cell lymphoma.
  • Camzyos (mavacamten): A treatment for symptomatic obstructive hypertrophic cardiomyopathy (HOCM).
  • Strategic partnership with MyoKardia: Expanding BMY's presence in the cardiovascular disease market.

Market Dynamics

Industry Trends:

The pharmaceutical industry is undergoing significant transformations, including:

  • Increased focus on personalized medicine and precision oncology.
  • Growing importance of digital health and technology.
  • Rise in biosimilars and generic competition.

BMY's Positioning and Adaptability:

BMY is well-positioned within the industry, with a strong pipeline of innovative medicines, a focus on key growth areas, and a commitment to adapting to market changes.

Competitors

Key Competitors:

  • Pfizer (PFE)
  • Merck (MRK)
  • Roche (RHHBY)
  • AbbVie (ABBV)
  • Amgen (AMGN)

Market Share and Comparison:

BMY holds a significant market share in several therapeutic areas, but it faces stiff competition from other major pharmaceutical companies.

Competitive Advantages and Disadvantages:

BMY's competitive advantages include its strong pipeline, innovative medicines, and global reach. However, the company faces challenges from generic competition and rising costs.

Potential Challenges and Opportunities

Key Challenges:

  • Generic competition for top products
  • Managing costs and expenses
  • Maintaining a strong pipeline of new medicines

Potential Opportunities:

  • Expanding into new therapeutic areas
  • Leveraging digital health and technology
  • Pursuing strategic acquisitions

Recent Acquisitions

Notable Acquisitions (2020-2023):

  • MyoKardia (2020): This acquisition expanded BMY's presence in the cardiovascular disease market, adding mavacamten, a promising treatment for obstructive hypertrophic cardiomyopathy (HOCM).
  • Celgene (2019): This major acquisition brought BMY a diverse portfolio of innovative medicines, including Revlimid, a blockbuster treatment for multiple myeloma.
  • Turning Point Therapeutics (2023): This acquisition strengthens BMY's position in the immuno-oncology market with the addition of repotrectinib, a highly selective tyrosine kinase inhibitor for the treatment of non-small cell lung cancer (NSCLC).

These acquisitions demonstrate BMY's commitment to expanding its product portfolio, entering new therapeutic areas, and driving future growth.

AI-Based Fundamental Rating

AI-Based Rating:

Based on an analysis of financial fundamentals, market position, and future prospects, BMY receives an AI-based rating of 8 out of 10.

Justification:

BMY's strong financial performance, innovative product portfolio, and favorable growth prospects make it an attractive investment opportunity. However, the company faces challenges from generic competition and rising costs, which could impact future growth.

Sources and Disclaimers

Sources Used:

Disclaimer:

This information is provided for educational purposes only and should not be considered investment advice.

About Bristol-Myers Squibb Company

Exchange NYSE
Headquaters Princeton, NJ, United States
IPO Launch date 1972-01-01
CEO & Chairman Dr. Christopher S. Boerner Ph.D.
Sector Healthcare
Industry Drug Manufacturers - General
Full time employees 34100
Full time employees 34100

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​